Trial site

Irvine Clinical Research

Irvine, California 92614, United StatesNot linked to an institution yet

19running trials
5closed trials

The trials here

What the 25 trials at this site are about, from their registry records.

Conditions: Alzheimer disease16 trials
Depression5 trials
Obesity3 trials
Type 2 diabetes2 trials
Chronic kidney disease1 trial
Coronary artery disease1 trial
Frontotemporal dementia1 trial
Heart failure1 trial
Insomnia1 trial
Lewy body dementia1 trial
Osteoarthritis1 trial
Peripheral artery disease1 trial
and 1 more
Phase: Phase 315 trials
Phase 26 trials
Phase 14 trials
Status: Active, not recruiting9 trials
Recruiting7 trials
Completed5 trials
Not yet recruiting3 trials
Suspended1 trial
Lead sponsor: Eli Lilly and Company17 trials
Xenon Pharmaceuticals Inc.2 trials
Bristol-Myers Squibb1 trial
Eisai Inc.1 trial
Green Valley (Shanghai) Pharmaceuticals Co., Ltd.1 trial
and 3 more

Running trials

Not yet recruiting
A Study of LY4560736 in Healthy Participants and Participants With Alzheimer's Disease (AD)
NCT07843459· Phase 1· Eli Lilly and Company· Source
Contact: Elly Lee (principal investigator)
Recruiting
A Master Protocol Studying Multiple Amyloid-Targeting Therapies in Healthy Participants and Participants With Alzheimer's Disease
NCT07787169· Phase 1· Eli Lilly and Company· Source
Contact: Elly Lee (principal investigator)
Recruiting
A Study of Brenipatide (LY3537031) in Adult Participants With Major Depressive Disorder
NCT07775300· Phase 3· Eli Lilly and Company· Source
Contact: Elly Lee (principal investigator)
Recruiting
A Study of Donanemab (LY3002813) in Participants Who Completed Study AACM (TRAILBLAZER-ALZ 3-EXT).
NCT07602582· Phase 3· Eli Lilly and Company· Source
Contact: Elly Lee (principal investigator)
Recruiting
A Study of LY3439539 in Participants With Alzheimer's Disease
NCT07598370· Phase 1· Eli Lilly and Company· Source
Contact: Elly Lee (principal investigator)
Recruiting
A Study of Donanemab (LY3002813) in Participants With Early Cognitive Decline (TRAILBLAZER-ALZ 7)
NCT07589595· Phase 2· Eli Lilly and Company· Source
Contact: Elly Lee (principal investigator)
Recruiting
A Study of Eloralintide (LY3841136) in Participants With Persistent Obesity Who Are Treated With a Weekly Incretin
NCT07392190· Phase 3· Eli Lilly and Company· Source
Contact: Elly Lee (principal investigator)
Recruiting
A Study of LY4405094 in Healthy Participants and Participants With Alzheimer's Disease
NCT07787182· Phase 1· Eli Lilly and Company· Source
Contact: Elly Lee (principal investigator)
Recruiting
A Study to Evaluate the Efficacy and Safety of KarXT + KarX-EC for Cognitive Impairment in Alzheimer's Disease (MINDSET 2)
NCT06976203· Phase 3· Bristol-Myers Squibb· Source
Contact: Elly Lee, Site 0095
Active, not recruiting
An Open-Label Study of Azetukalner in Major Depressive Disorder
NCT06922110· Phase 3· Xenon Pharmaceuticals Inc.· Source
Recruiting
Zelquistinel or Placebo for the Reduction of Symptoms of Major Depressive Disorder
NCT06547489· Phase 2· Syndeio Biosciences, Inc· Source
Contact: Karen Raudibaugh
Active, not recruiting
A Randomized Study of Azetukalner Versus Placebo in Major Depressive Disorder
NCT06775379· Phase 3· Xenon Pharmaceuticals Inc.· Source
Active, not recruiting
A Study of Remternetug (LY3372993) in Early Alzheimer's Disease (TRAILRUNNER-ALZ 3)
NCT06653153· Phase 3· Eli Lilly and Company· Source
Active, not recruiting
A Study of JNJ-64042056 in Participants With Preclinical Alzheimer's Disease
NCT06544616· Phase 2· Janssen Pharmaceutica N.V., Belgium· Source
Active, not recruiting
The Effect of Retatrutide Once Weekly on Cardiovascular Outcomes and Kidney Outcomes in Adults Living With Obesity (TRIUMPH-Outcomes)
NCT06383390· Phase 3· Eli Lilly and Company· Source
Active, not recruiting
A Study of Different Donanemab (LY3002813) Dosing Regimens in Adults With Early Alzheimer's Disease (TRAILBLAZER-ALZ 6)
NCT05738486· Phase 3· Eli Lilly and Company· Source
Active, not recruiting
A Donanemab (LY3002813) Study in Participants With Preclinical Alzheimer's Disease (TRAILBLAZER-ALZ 3)
NCT05026866· Phase 3· Eli Lilly and Company· Source
Active, not recruiting
A Study of Donanemab (LY3002813) in Participants With Early Alzheimer's Disease (TRAILBLAZER-ALZ 2)
NCT04437511· Phase 3· Eli Lilly and Company· Source
Active, not recruiting
A Study to Confirm Safety and Efficacy of Lecanemab in Participants With Early Alzheimer's Disease
NCT03887455· Phase 3· Eisai Inc.· Source

Recruiting at the same time

How many trials recruit for the same indication here at once. A count, not a rating.

Alzheimer disease7 recruiting
Depression2 recruiting
Lewy body dementia1 recruiting
Obesity1 recruiting
Type 2 diabetes1 recruiting

Closed trials

Completed
A Study of Tirzepatide (LY3298176) Plus Mibavademab Compared With Tirzepatide Alone in Adult Participants With Obesity
NCT06373146· Phase 2· Eli Lilly and Company· Source
Completed
A Study of Remternetug (LY3372993) in Participants With Alzheimer's Disease (TRAILRUNNER-ALZ 1)
NCT05463731· Phase 3· Eli Lilly and Company· Source
Completed
A Study of LY3372689 to Assess the Safety, Tolerability, and Efficacy in Participants With Alzheimer's Disease
NCT05063539· Phase 2· Eli Lilly and Company· Source
Completed
A Study of Seltorexant as Adjunctive Therapy to Antidepressants in Adult and Elderly Participants With Major Depressive Disorder With Insomnia Symptoms Who Have Responded Inadequately to Antidepressant and Long-term Safety Extension Treatment With Seltorexant
NCT04533529· Phase 3· Janssen Research & Development, LLC· Source
Recruiting
A Master Protocol Study (LY900028) of Multiple Intervention-Specific-Appendices (ISAs) in Participants With Chronic Pain
NCT05986292· Phase 2· Eli Lilly and Company· Source

Site data: ClinicalTrials.govUpdated 13 Nov 2026

Report an error